Four years after manufacturing problems cost Sanofi-owned Shantha Biotechnics a $340 million contract to supply pentavalent vaccine Shan5, the jab has rewon the World Health Organization's favor, nabbing a positive prequalification decision that opens the door for purchases by United Nations agencies.
Sanofi's plan for revamping Shantha Biotech won Indian government approval, clearing the way for it to recapture WHO contracts for its Shan5 vaccine.
Sanofi ($SNY) subsidiary Shantha Biotechnics has told The Hindu Business Line it plans to relaunch its pentavalent vaccine, Shan5, next year after a new WHO audit. In August 2010, the World Health
Sanofi ($SNY) subsidiary Shantha Biotech plans to relaunch the company's pentavalent Shan5 vaccine in 2013. The vaccine was removed from the World Health Organization's prequalification list...
The year 2013 still appears correct for Sanofi's ($SNY) relaunch of its Shantha Biotech unit's Shan5 pentavalent vaccine, sidelined in 2010 by the World Health Organization because of a white residue
Sanofi-Aventis ($SNY) expects its Shantha Shan5 vaccine for five childhood diseases to be off the market until 2013 while it rebounds from manufacturing issues that yielded white sediment in some
Sanofi's loss is Crucell's gain. As pediatricians in Kathmandu work to calm parents unable to have their infants vaccinated against five diseases, Sanofi Aventis' Indian unit Shantha is scrambling to